The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I fixed-dose feasibility study of MK615 and gemcitabine in patients with advanced or metastatic pancreatic cancer.
 
Ichiro Moriyama
Honoraria - Taiho Pharmaceutical
 
Fumiyoshi Ikejiri
No Relationships to Disclose
 
Koshi Kawakami
No Relationships to Disclose
 
Masaya Inoue
No Relationships to Disclose
 
Satoshi Kumanomido
No Relationships to Disclose
 
Matsuda Shinichiro
No Relationships to Disclose
 
Fumimasa Takahashi
No Relationships to Disclose
 
Shunsuke Ito
No Relationships to Disclose
 
Yusuke Okada
No Relationships to Disclose
 
Hiroshi Mochida
No Relationships to Disclose
 
Yasumasa Shimazaki
No Relationships to Disclose
 
Norimi Ugata
No Relationships to Disclose
 
Takahiro Okada
No Relationships to Disclose
 
Yumi Jo
No Relationships to Disclose
 
Chie Onishi
No Relationships to Disclose
 
Tsutomu Takahashi
No Relationships to Disclose
 
Takaaki Miyake
No Relationships to Disclose
 
Ritsuro Suzuki
Honoraria - Bristol-Myers Squibb; Celgene; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Meiji Seika Kaisha; Mochida Pharmaceutical Co. Ltd.; MSD; Novartis; Otsuka; Sanofi; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Takeda
Consulting or Advisory Role - Gilead Sciences; Jazz Pharmaceuticals; Mundipharma
 
Junji Suzumiya
Speakers' Bureau - Alexion Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Celgene; Chugai/Roche; Eisai; Gilead Sciences; Janssen; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Shire; Sumitomo Dainippon; Takeda; Zenyaku Kogyo
Research Funding - Astellas Medivation (Inst); Chugai/Roche (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Rexahn Pharmaceuticals (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda; Toyama Chemical Co (Inst); Yakult Honsha (Inst)